Table 2.
Patient´s characteristics at the time of re-irradiation and outcomes
| RT1-RT2 (months) | RT1-failure-RT2 (months) | Chemotherapy before RT2 | Surgery before RT2 | RT2 total Gy; dose per fraction | Site RT2 | RT2 failure | Location RT2 failure* | TTP 2 or last follow up (months) | FU after RT2 (months) | Current status | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Local relapses | |||||||||||
| HypoFFRT | |||||||||||
| 1 | 52 | 2 | No | GTR | 35; 3.5 | 4th ventricle | No | DA | 25 | 25 | NED |
| 2 | 37 | 3 | No | GTR | 44; 4.4 | 4th ventricle | Yes | Metastatic | 11 | 34 | NED |
| 3 | 35 | 3 | No | GTR | 35; 3.5 | 4th ventricle | Yes | Infield | 31 | 31 | PD |
| 4 | 46 | 2 | No | GTR | 27; 4.5 | 4th ventricle | Yes | Metastatic | 15 | 57 | DOD |
| 5 | 16 | 4 | No | GTR | 35; 3.5 | Left parietal | Yes | Margin/mets | 5 | 12 | DOD |
| 6 | 22 | 3 | No | GTR | 25; 5 | Left parietal | No | DA | 37 | 37 | NED |
| 7 | 27 | 1 | No | NS | 14 | Left cerebellar | No | DA | 99 | 99 | NED |
| 8 | 34 | 1 | No | GTR | 36; 6 | 4th + Left lateral V | No | DA | 12 | 12 | NED |
| FFRT | |||||||||||
| 9 | 44 | 33 | Yes | STR | 50.4; 1.8 | Left temporal | Yes | Infield | 19 | 27 | DOD |
| 10 | 70 | 9 | No | NS | 54; 1.8 | Right CP angle | Yes | Infield | 14 | 24 | NED |
| 11 | 31 | 18 | No | GTR | DA | Parietal | Yes | Infield | 0 | 2 | DOD |
| 12 | 12 | 3 | Yes | STR | 37.5; 2.5 | Fronto-parietal | Yes | Margin/mets | 3 | 19 | DOD |
| 13 | 23 | 5 | No | GTR | 45; 1.8 | 4th ventricle | Yes | Infield/margin | 9 | 35 | DOD |
| 14 | 88 | 2 | No | GTR | 59.4; 1.8 | Temporo-parietal | No | DA | 6 | 6 | NED |
| 15 | 38 | 2 | No | GTR | 54; 1.8 | 4th ventricle | No | DA | 69 | 69 | NED |
| Metastatic relapses | |||||||||||
| HypoFFRT | |||||||||||
| 16 | 69 | 4 | No | GTR | 51; 5.1 | Right temporal | Yes | Metastatic | 2 | 15 | DOD |
| 17 | 17 | 5 | No | GTR | 45; 3 | Frontal | No | DA | 17 | 17 | NED |
| 18 | 19 | 17 | No | GTR | 37.5; 6.25 | Left lateral ventricle | No | DA | 9 | 9 | NED |
| FFRT and spinal RT | |||||||||||
| 19 | 51 | 6 | Yes | STR | 54; 2.25 | Suprasellar | Yes | Metastatic | 7 | 33 | DOD |
| 20 | 9 | 2 | No | STR | 35 + 15; 1.8 | SP(B L3-TS) | Yes | Metastatic | 8 | 22 | DOD |
| 21 | 12 | 2 | Yes | GTR | 54; 1.8 | Fronto-parietal | Yes | Metastatic | 2 | 35 | DOD |
| 22 | 8 | 3 | No | STR | 35 + 18; 1.8 | SP(B TS) | Yes | Metastatic | 15 | 42 | DOD |
| 23 | 15 | 1 | No | GTR | 54; 1.8 | L4-S3 | Yes | Metastatic | 11 | 18 | NED |
| 24 | 6 | 2 | Yes | STR | 35 + 10; 1.8 | SP(B T9-L1) | Yes | Metastatic | 6 | 9 | DOD |
| 25 | 10 | 2 | No | STR | 36 + 14; 1.8 | SP(B TS) | Yes | Metastatic | 13 | 25 | DOD |
| CSI | |||||||||||
| 26 | 15 | 13 | Yes | NS | 40 + 15; 1.8 | BR (B PF) | No | DA | 140 | 140 | NED |
| 27 | 105 | 5 | No | GTR | 36 + 14; 1.8 | BR(PPF)/SP(B TS) | No | DA | 83 | 83 | NED |
| 28 | 14 | 1 | Yes | STR | 36; 1.8 | BR (PPF)/SP | Yes | Metastatic | 2 | 8 | DOD |
| 29 | 35 | 27 | No | NS | 45/36; 1.8 | BR/SP | Yes | Infield | 40 | 99 | DOD |
| 30 | 16 | 4 | Yes | STR | 30/36 + 18; 1.8 | BR(PPF)/SP(B C) | No | DA | 11 | 11 | NED |
| 31 | 27 | 2 | No | NS | 40; 1.8 | BR/SP to L1 | No | DA | 69 | 69 | NED |
| 32 | 17 | 2 | Yes | STR | 36 + 9; 1.8 | BR (PPF)/SP(B C) | Yes | Metastatic | 6 | 8 | DOD |
B boost, BR brain, CSI craniospinal irradiation, C conus, DA does not apply, DOD dead of disease, FFRT focal fractionated radiotherapy, FU follow up, GTR gross total resection, HypoFFRT hypofractionated stereotactic radiotherapy, Mets metastatic, NED no evidence of disease, NS no surgery, PD progressive disease, PF posterior fossa, PPF protection posterior fossa, STR subtotal resection, SP spinal axis, TTP time to progression, TS thecal sac, V ventricule
* Location RT2 failure regarding RT2 field infield at margin and metastatic